Across 11 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the full record of transactions filed by Edgemond James, Chief Financial Officer. Director active across 1 company, notably UNITED THERAPEUTICS Corp. Aggregated, 258 disclosures have been recorded. Split: 0 buy · 215 sells. Total volume traded: €73.4m. History available since 7 November 2022. The latest transaction was filed on 4 June 2026 (Cession). Regulator: SEC (Form 4). All data is free.
Companies and markets linked to Edgemond James
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
James Edgemond is the Chief Financial Officer and Treasurer of United Therapeutics Corp. In this role, he is responsible for the company's financial management, including financial planning and risk management. James brings expertise in finance and accounting, contributing to United Therapeutics' performance and growth. His commitment to financial transparency is essential for maintaining investor trust.